Targeting mTORC1 activation during lung injury

Discovering mTORC1’s role as a mechanosensor in lung injury during ventilation. Reshaping respiratory medicine.

Nanoparticle drug delivery for ARDS

Prior ARDS trials used systemic delivery but didn’t succeed. Our inhaled lipid nanoparticles with miR-146a prevent lung injury in mechanosensitive lung macrophages.

Zinc metabolism in ARDS

Zinc deficiency increases lung injury risk during ventilation. Our study with 650 ICU patients may lead to a clinical trial for ARDS zinc supplementation.

Translation studies of critically-ill ICU patients

Dr. Englert collaborates on biorepositories, investigating ARDS mechanisms in diverse patient groups and participating in 30+ ICU clinical trials.